

Decreased Superoxide Dismutase Activity after ECT and Correlation between Higher Oxidant Levels and Poor Response to ECT in Depression

Depresyonda EKT Sonrası Süperoksit Dismutaz Aktivitesi Düşüyor ve EKT'ye Kötü Yanıtla Korelasyon Gösteriyor

Osman VİRİT, Alican DALKILIÇ*, Mahmut BULUT, Feridun BÜLBÜL, Abdurrahman ALTINDAĞ, Ferah ARMUTÇU**, Esra KOÇOĞLU***, Serhat ÇITAK****, Haluk Asuman SAVAŞ

Department of Psychiatry, School of Medicine, Gaziantep University, Gaziantep, Turkey

*St. Elizabeths Hospital, Washington, DC; Virginia Commonwealth University, Richmond, VA, USA

**Department of Biochemistry, School of Medicine, Fatih University, Ankara, Turkey

***Department of Microbiology, School of Medicine, Abant İzzet Baysal University, Bolu, Turkey

****Department of Psychiatry, Erenkoy Training and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey

ABSTRACT

Objective: The literature regarding effects of electroconvulsive therapy (ECT) on oxidative metabolism (OM) reports conflicting changes in oxidant and antioxidant status in animal studies. The goal of this first human study was to investigate the changes in oxidants and antioxidants in plasma of depressed patients after ECT.

Methods: Fourteen unipolar and two bipolar patients were included in the study. The blood samples were obtained within one hour before the 1st and within one hour after the 7th ECT sessions. Oxidants malondialdehyde (MDA), nitric oxide (NO), and xanthine oxidase (XO) and antioxidant superoxide dismutase (SOD) were measured in the plasma.

Results: Before the 1st and after the 7th ECT sessions, the Hamilton Depression Rating Scale (HDRS) scores were 32.63±9.54 and 16.50±7.22, respectively (t=7.92, df=15, p<0.001). After the 7th ECT, SOD values were significantly lower than pre-ECT SOD values (p<0.05, Z= -3,459). There were no significant difference between pre-and post-ECT values of MDA, NO, and XO (p>0.05). However, pre-ECT SOD values were significantly and positively correlated with pre-ECT HDRS scores (r=0.641, p=0.007).

Conclusion: The decrease in antioxidant enzyme SOD after ECT may damage the neurons by increasing oxidative stress. Thus, possible benefits of antioxidant supplementation during ECT should be investigated. Additionally, higher pre-ECT oxidant levels may predict a poor response to ECT in depression. (*Archives of Neuropsychiatry 2010; 47: 247-51*)

Key words: Electroconvulsive therapy, Oxidative metabolism, Superoxide dismutase

ÖZET

Amaç: Elektrokonvülfif tedavinin (EKT) oksidatif metabolizma üzerine etkileri ile ilgili literatürün çoğu hayvan deneylerine dayanmaktadır ve oksidan/antioksidan dengenin değiştiğine dair çelişkili sonuçlar içermektedir. Bu alanda yapılan ilk insan çalışması olan bu çalışmanın amacı depresif hastalarda EKT sonrası oksidan ve antioksidanlardaki değişimleri araştırmaktır.

Yöntemler: On dört unipolar ve iki bipolar depresyon hastası çalışmaya dahil edildi. Kan örnekleri ilk EKT seansından 1 saat önce ve 7. EKT seansından 1 saat sonra alındı. Plazmada oksidanlardan malondialdehit (MDA), nitrik oksit (NO) ve ksantin oksidaz (XO); antioksidanlardan süperoksit dismutaz (SOD) seviyeleri ölçüldü.

Bulgular: Birinci ve 7. EKT seansından sonraki Hamilton Depresyon Ölçeği (HAM-D) skorları 32.63±9.54 ve 16.50±7.22 idi (t=7.92, df=15, p<0.001). Yedinci EKT sonrası SOD değerleri EKT öncesi SOD değerlerinden anlamlı olarak düşüktü (p<0.05, Z= -3,459). EKT öncesi ve sonrası MDA, NO ve XO değerleri arasında anlamlı bir farklılık yoktu (p>0.05). Bununla birlikte, EKT öncesi SOD değerleri EKT öncesi HAM-D skorları ile anlamlı düzeyde pozitif korelasyon gösteriyordu (r=0.641, p=0.007).

Sonuç: EKT sonrası antioksidan bir enzim olan SOD düzeyindeki düşüş oksidatif stresi arttırarak nöronlara zarar verebilir. Bu nedenle EKT uygulama dönemlerinde antioksidan ekleme tedavilerinin olası faydaları araştırılmalıdır. Yine EKT öncesi yüksek oksidan seviyeleri depresyon hastalarında EKT'ye kötü yanıtı yordayabilir. (*Nöropsikiyatri Arşivi 2010; 47: 247-51*)

Anahtar kelimeler: Elektrokonvülfif tedavi, Oksidatif metabolizma, Süperoksit dismutaz

Introduction

Electroconvulsive therapy (ECT) has been used as a treatment for mental disorders since 1938. For refractory depression it is still the most effective treatment (1). A brief electrical stimulus is delivered to the brain through external electrodes and a cerebral seizure is induced under controlled conditions (2). Some cognitive adverse events may occur due to ECT (3). The hippocampus, frontal cortex, striatum, entorhinal cortex, temporal-parietal cortex are primary brain regions impacted by ECT (4).

The findings from a study of electroconvulsive shock (ECS), the animal equivalent of ECT, on animals have contributed to explain the therapeutic effect of ECT (5). In neurotransmitters and their receptors in the brain, ECS produces various changes, many of which can be linked to its therapeutic effect. Chronic ECS application influences 5-hydroxytryptamine (5-HT) 1A receptors, β -adrenoreceptors, α 2-adrenoreceptors, adenosine A1 receptors, muscarinic receptors (6) and N-methyl-D-aspartic acid (NMDA) receptor complex (7). ECS also activates cell signaling and leads to release of second messengers (8). Protein and lipid changes in cell membrane and activations within the cell result in intracellular free fatty acid accumulation, which in turn causes formation of eicosanoids, lipid peroxides, and free radicals [9]. Antioxidant mechanisms try to minimize the cellular damage by removing hazardous oxidants (10).

In ECS studies on rats, conflicting values of oxidants and antioxidants were observed at various regions of the brain. While some researchers found an increase (4) in oxidants, others measured a decrease (11); meanwhile, Jornada et al. [12] reported no significant changes in oxidative metabolites after ECS. Regarding antioxidants, Erakovic et al. (10) and Feier et al. [4] measured a decrease, but Baricello et al. (11) found an increase.

As we could not identify any literature about ECT and oxidative metabolism relationship in the human brain or blood, we conducted this study to investigate the changes in oxidants and antioxidants in the plasma of depressed patients after ECT. We studied plasma levels of nitric oxide (NO), xanthine oxidase (XO) and malondialdehyde (MDA) as oxidants and activity of superoxide dismutase (SOD) as antioxidant.

Methods

Patients

A total of 16 consequent patients were included in the study. They were admitted for ECT after being assessed by one psychiatrist (HAS) at the Psychiatry Clinic of Gaziantep School of Medicine. Based on DSM-IV (13) criteria, all patients had been diagnosed with unipolar depression, except two, who met criteria for bipolar depression. All participating patients provided written informed consent separately for ECT and this study after standard education about ECT and the study protocol. The protocol had been approved by the Institutional Review Board of Gaziantep University, School of Medicine in accordance with the Declaration of Helsinki. ECT indication criteria were limited to presence of catatonic or psychotic features, significant suicide risk, or lack of response to at least two antidepressants at adequate doses after adequate duration of treatment.

Exclusion criteria included alcohol or substance abuse or dependence, presence of severe organic disorders, use of any

antioxidants such as vitamin E or C, presence of epilepsy or other severe neurological disorders, presence of any infectious or viral disease, presence of diabetes mellitus or excessive obesity, and other severe medical conditions. Routine electrocardiogram, chest X-ray, complete blood count and blood chemistry panel were obtained from all patients prior to ECT. These routine tests were used to detect possible problems for exclusion criteria. All patients continued their outpatient medication regimen, which included antidepressants, antipsychotics, lithium, or benzodiazepines during ECT treatment. No medication or dose changes were made during the study.

The mean age of the patients was 39 ± 17.98 years. Seven (43.8%) of them were men and 9 (56.2%) were women. Fourteen (87.5%) patients had previous history of ECT, 11 patients (68.8%) had previous inpatient psychiatric treatment and 4 (25%) patients had positive psychiatric family history. The mean illness duration was 3.44 ± 3.18 (range 1-9) years. Two (12.5%) patients had comorbid medical disease, 14 (87.5%) did not. The comorbid medical diseases were migraine and gonarthrosis, which were not included in the exclusion criteria.

The severity of depression and response to the treatment were assessed by the 17-item Hamilton Depression Rating Scale (HDRS) [14]. The ratings were performed before the 1st and after the 7th ECT sessions. The HDRS was adapted for use in Turkish speaking patients with established validity and reliability (15).

ECT procedure

Each patient received at least 7 ECT treatments; there were no upper limit regarding the number of ECTs. In order to establish a standard among the subjects, blood samples for testing were obtained within 1 hour before the 1st ECT and within 1 hour after the 7th ECT sessions. ECT sessions were carried out under general anesthesia 3 times per week. The anesthesia procedure consisted of administration of propofol (1 mg/kg), an anesthetic agent considered to have no opioid or glucocorticoid properties, and succinylcholine (0.5 mg/kg) and oxygenation. ECT was delivered through bitemporally (one in each temporal fossa) placed classical electrodes between 09.00AM and 11.00 A.M. after overnight fasting. The current was sinusoidal, and the stimulus intensity was standardized at 700 mA for 5 seconds. Seizures were monitored by the cuff method. ECT was administered using a T-03 Basak Elektronik (Başak Elektronik, Istanbul, Turkey) machine. Seizure durations of 30-60 seconds were generated at each ECT session for each patient.

Blood collection and biochemical analyses

Blood samples were collected from the antecubital veins of each patient into 5 ml vacutainer tubes within one-hour period before the first ECT and within one hour after the 7th ECT sessions performed after an overnight fast. Blood samples were taken to normal laboratory tubes without anticoagulants. After immediate centrifugation (1000g, 10 min), serum samples were stored frozen at -70 °C. The biochemical analyses were performed at Biochemistry Laboratories of Gaziantep University, School of Medicine after the blood samples of all patients were collected.

Measurement of XO level

Plasma XO activity was measured spectrophotometrically by the formation of uric acid (UA) from xanthine through the increase in absorbance at 293 nm (Prajda and Weber, 1975). A calibration curve was constructed by using 10–50 milliunits/ml concentrations of standard XO solutions (Sigma X-1875). One unit of activity was defined as 1 mmol UA formed per minute at 37°C and pH 7.5. Results were expressed in units per liter plasma.

Measurement of NO level

The stable oxidation end products of NO, nitrite (NO_2^-) and nitrate (NO_3^-) were measured as indicators of NO production [16]. For nitrite plus nitrate (total nitrite) detection, an aliquot of the sample was treated with copperized cadmium (Cd) in glycine buffer at pH 9.7 (2.5 to 3g of Cd granules for a 4 mL reaction mixture) to reduce nitrate to nitrite and then mixed with fresh reagent, and the absorbance was measured in a spectrophotometer (UV-1601 Shimadzu, Japan). Linear regression was done using the peak areas from the nitrite standards. The resulting equation was then used to calculate the unknown sample concentrations. All chemicals used in this assay were obtained from Sigma, except cadmium granules. The results were expressed as micromoles per liter ($\mu\text{mol/L}$).

Measurement of MDA level

The plasma MDA levels were determined by the method of Draper and Hadley (1990) based on the reaction of MDA with thiobarbituric acid (TBA) at 95°C. In the TBA test reaction, MDA and TBA react to form a pink pigment with an absorption maximum at 532 nm. The reaction was performed at pH 2-3 at 95 °C for 15 minutes. The sample was mixed with 2.5 volumes of 10% (w/v) trichloroacetic acid to precipitate the protein. The precipitate was pelleted by centrifugation and an aliquot of the supernatant was allowed to react with an equal volume of 0.67% TBA in a boiling water bath for 15 minutes. After cooling, the absorbance was read at 532 nm. Arbitrary values obtained were compared with a series of standard solutions (1,1,3,3 tetramethoxypropane). The results were expressed as nmol/mL.

Measurement of SOD activity

The principle of the total SOD activity method is based, briefly, on the inhibition of nitroblue tetrazolium (NBT) reduction by O_2^- U generated by xanthine/xanthine oxidase system (17,18). One unit of SOD was defined as the enzyme amount causing 50% inhibition in the NBT reduction rate. Activity was expressed as Units per milliliter serum (U/mL).

Data analysis

SPSS 13.0 for Windows (SPSS, Chicago, IL) was used for the statistical analysis of data. The Wilcoxon signed-rank test was performed to compare the mean values obtained before and after the treatment. The differences were considered significant when p value was less than 0.05. Bivariate statistics were performed using Spearman's rho. Two-tailed significance values were used.

Results

We did not find any significant relationship between oxidants and antioxidant and following variables: gender, illness duration, number of inpatient episodes, history of previous ECT treatment, comorbid medical diseases and family psychiatric history ($p>0.05$).

Post-7th ECT values were significantly lower than pre-1st ECT SOD ones ($p<0.05$, $Z = -3.155$). No significant differences were detected between pre-1st ECT MDA, NO, XO and post-7th ECT MDA, NO and XO values ($p>0.05$). Pre-1st ECT and post-7th ECT MDA, NO, XO, SOD values are listed in Table 1. Pre-1st ECT and post-7th ECT HDRS scores were 32.63 ± 9.54 (mean \pm SD) (range: 27-37), and 16.50 ± 7.22 (mean \pm SD) (range: 12-20), ($Z: -3.519$, $p<0.0001$), respectively.

The depression in three patients showed psychotic features. There was no significant difference between patients with and without psychotic features with regard to pre- and post-ECT SOD, MDA, NO and XO values.

There was a significant positive correlation between pre-1st ECT SOD and pre-1st ECT HDRS scores ($r=0.641$, $p=0.007$). In other words, as the severity of depression increased, so did pre-1st ECT SOD values. In addition, we found a significant negative correlation between pre-1st ECT NO ($r=-0.563$, $p=0.02$) and pre-1st ECT XO ($r=-0.584$, $p=0.018$) levels and HDRS total score changes from pre-1st ECT to post-7th ECT. Otherwise, as pre-1st ECT NO and XO values got higher, the drop in HDRS scores after ECT treatment became smaller.

Discussion

The first important finding of this study was that post-7th ECT SOD were significantly lower than pre-1st ECT SOD, while there were no significant differences between pre-1st ECT NO, XO, and MDA and post-7th ECT NO, XO, and MDA values, respectively, in the plasma of depressed patients.

We could not identify any study on this topic with ECT in humans in the literature, but there are animal studies about oxidant and antioxidant levels with different ECS applications to various areas of the brain in rats. Similar to our results Erakovic et al. (10) reported that single or repeated ECS induced a decrease in SOD and glutation peroxidase (GPX) activities at various brain regions in rats. Baricello et al. (11) demonstrated an increase in catalase (CAT) and SOD activities, a decrease in lipid peroxidation, and protein damage in the hippocampus immediately after and up to 30 days after a single or multiple ECS. Feier et al. (4) found a delayed increase in oxidative damage after ECS and a decrease in SOD and CAT activities in hippocampus and striatum in rats. Jornada et al. [12] reported no alteration in the lipid peroxidation and no protein damage in the hippocampus, cortex, cerebellum, and striatum immediately after, 48 h and 7 days after the last maintenance ECS. Zupan et al. (19) found oxidative lipid damage only in the frontal cortex, but not in the hippocampus, cerebellum, and the pons/medulla region in their experimental animal conditions. Also they reported that the SOD and GPX activities significantly increased in the hippocampus and cerebellum, but did not change in the pons/medulla region.

The exact cause of decrease in SOD in our study is not known. As suggested in an animal study, oxidative stress and accumulation of hydrogen peroxide, which inactivates SOD irreversibly, possibly disturbs the SOD synthesis by damaging the mitochondrial function [20]. The mentioned oxidants were not increased in our study, but some oxidative products resulting from increased neuronal activity after ECT might have caused SOD inhibition. In addition, collecting blood samples before adequate normalization of SOD might have resulted in lower SOD levels after the 7th ECT (10).

Decrease in SOD levels may lead to deficiency in oxidative defense, and hence causes oxidative stress, which has hazardous effects on neurons. Interestingly, a study in rats reported an association between a decrease in SOD activity in frontal cortex and amnesia after ECT (21). In another significant report in the literature, it was observed that exogenously

administered enzymatic and non-enzymatic antioxidants successfully protected the brain against seizure-induced damage (10).

It is important to note that these studies were conducted in rats, and the measurements were done at different regions of rat brains, while our results were obtained from plasma of depressed humans. The human studies investigating oxidant and antioxidant changes in antidepressant receiving depressed patients resulted in a variety of findings. Herken et al. (2007) found no change in NO levels, but XO and adenosine deaminase (ADA) levels were significantly higher in major depressive disorder (MDD) patients, and SOD activity was significantly lower than in the controls. After 8 weeks of antidepressant treatment, ADA and SOD activities increased, and NO and XO levels decreased significantly. They concluded that ADA, XO, and SOD activity might have a pathophysiological role in MDD and predict the prognosis of MDD. The activity of these enzymes might be used to monitor the response to treatment. Selek et al. (22) discovered that NO was higher and SOD activity was lower in bipolar depression patients prior to treatment than in the controls. After 30 days treatment with antidepressants, mood stabilizers, other drugs, or ECT, NO levels normalized, but SOD levels remained low. Bilici et al. (23) reported that MDD patients, especially patients with melancholia, had higher antioxidant enzyme activity and lipid peroxidation levels than healthy controls. After 3 months treatment with selective serotonin reuptake inhibitors (SSRIs), both measurements decreased to normal levels.

The second important finding of this study was the discovery of some relationships between oxidant and antioxidant levels and depression severity, and also response to ECT. There was a significant positive relationship between pre-1st ECT SOD activity and before 1st ECT HDRS scores. Basically, high HDRS scores were correlated with high SOD1 activity, which may indicate a reactive antioxidant response by the body to severe depression (24). In addition, there was a significant negative correlation between NO1 and XO1 levels and decreases in HDRS total scores obtained before the 1st ECT and after the 7th ECT sessions. In other words, the higher the NO1 and XO1 levels were, the smaller the decreases were between pre-ECT and post-ECT HDRS scores. High oxidant levels might have impacted the response to ECT negatively; hence, the levels of oxidants prior to

ECT may be a factor in determining ECT responsiveness. This is an important finding and further research is needed. Some authors studied associations between oxidative metabolism (OM) and severity of illness and response to pharmacotherapy in depressed patients. Herken et al. (25) found no correlation between HDRS scores and SOD, ADA, XO and NO levels. Bilici et al. (23) reported a positive correlation between erythrocyte SOD levels and HDRS scores and suggested that antidepressant treatment decreased SOD levels. They also proposed that antioxidant enzyme activity might be used to monitor the response to SSRIs in MDD.

Some important limitations of this study include relatively low number of patients, lack of control group, and missing data regarding smoking status of patients. Smoking status might have possibly interfered with the results as a confounding factor, only if any change occurred during the study (26). The patients likely did not change their smoking habits during short study period. All patients continued their medication regimen during ECT course. Despite no medication and dosage changes, ECT outcome and oxidative parameters might possibly have been effected (23). Finally, propofol, which was used for anesthesia, was demonstrated to decrease oxidant enzyme activities. However, some reports mentioned that it had no effect on SOD (27,28). Theoretically, it is possible that the oxidant enzyme activities were decreased by propofol and increased back by ECT. The possible effect of propofol, given one hour before blood sampling, on oxidative status is also a limitation of this study.

In conclusion, there were two important results of this study: The first one was the decrease in antioxidant enzyme SOD after ECT, which may cause oxidative stress by weakening the oxidative defenses. Oxidative stress may hazard neurons through adverse events. Regarding this finding, effect(s) of antioxidant supplementation during ECT should be investigated separately. The second result is that high oxidant (NO1 & XO1) levels before the 1st ECT session were significantly correlated with a poorer response to ECT. In other words, oxidative status might determine or predict the response to ECT in depressed patients. Future studies with larger and controlled designs should explore the effects of ECT on OM in humans. Furthermore, OM may be investigated under single, multiple, and maintenance ECT courses at different time points.

Table 1. Values of SOD, MDA, NO and XO at before 1st and after 7th ECT

		Mean±SD	Range	Statistic
SOD (U/mL)	Before 1 st ECT	5.82±1.16	3.99-7.84	p<0.002, Z= -3.155
	After 7 th ECT	4.19±0.64	3.26-5.69	
MDA (nmol/mL)	Before 1 st ECT	1.49±0.43	0.78-2.19	p>0.05, Z= -1.422
	After 7 th ECT	1.27±0.33	0.81-2.15	
NO (mmol/L)	Before 1 st ECT	28.93±8.66	16.27-48.82	p>0.05, Z= -1.448
	After 7 th ECT	31.97±5.69	23.50-39.78	
XO (U/L)	Before 1 st ECT	0.11±0.02	0.08-0.16	p>0.05, Z= -0.283
	After 7 th ECT	0.11±0.02	0.09-0.16	

SD: Standart Deviation

Abbreviations

ECT, electroconvulsive therapy; ECS, electroconvulsive shock; OM, oxidative metabolism; MDA, malondialdehyde; NO, nitric oxide; XO, xanthine oxidase; SOD, superoxide dismutase; TBA, thiobarbituric acid; GPX, glutathione peroxidase activities; CAT, catalase; ADA, adenosine deaminase; HDRS, Hamilton Depression Rating Scale; MDD, major depressive disorder; SSRI, selective serotonin reuptake inhibitor.

References

1. The UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* 2003; 361:799-808. [Abstract] / [Full Text] / [PDF]
2. Awata S, Konno M, Kawashima R, et al. Changes in regional cerebral blood flow abnormalities in late-life depression following response to electroconvulsive therapy. *Psychiatry Clin Neurosci* 2002; 56:31-40. [Abstract] / [Full Text] / [PDF]
3. Devanand DP, Dwork AJ, Hutchinson ER, et al. Does ECT alter the brain structure? *Am J Psychiatry* 1994; 151:957-70. [Abstract] / [PDF]
4. Feier G, Jornada LK, Barichello T, et al. Long lasting effects of electroconvulsive seizures on brain oxidative parameters. *Neurochem Res* 2006; 31:665-70. [Abstract] / [PDF]
5. Newman ME, Gur E, Shapira B, et al. Neurochemical mechanism of action of ECS: evidence from in vivo studies. *J ECT* 1998; 14:153-71. [Abstract]
6. Gleiter CH, Nutt DJ. Chronic electroconvulsive shock and neurotransmitter receptors. An update. *Life Sci* 1989; 44:985-1006. [Abstract] / [PDF]
7. Nowak G, Kata M, Jopek R, et al. Chronic electroconvulsive treatment increases the activity of nitric oxide synthase in the rat brain. *Pol J Pharmacol* 1997; 49:379-82. [Abstract]
8. Visioli F, Rodriguez de Turco E, Bazan NG. Daily electroconvulsive shock treatment alters the inositol lipid system response in the rat hippocampus. *Neurochem Res* 1994; 19:705-8. [Abstract] / [PDF]
9. Dugan LL, Choi DW. Excitotoxicity, free radicals, and cell membrane changes. *Ann Neurol* 1994; 35:17-21. [Abstract] / [PDF]
10. Eraković V, Zupan G, Varljen J, et al. Electroconvulsive shock in rats: changes in superoxide dismutase and glutathione peroxidase activity. *Brain Res Mol Brain Res* 2000; 76:266-74. [Abstract] / [Full Text] / [PDF]
11. Barichello T, Bonatto F, Feier G, et al. No evidence for oxidative damage in the hippocampus after acute and chronic electroshock in rats. *Brain Res* 2004; 1014:177-83. [Abstract] / [Full Text] / [PDF]
12. Jornada LK, Feier G, Barichello T, et al. Effects of maintenance electroshock on the oxidative damage parameters in the rat brain. *Neurochem Res*. 2007; 32:389-94. [Abstract] / [PDF]
13. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 4th ed. Washington, DC, American Psychiatric Association, 1994.
14. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; 23:56-62. [Abstract] / [PDF]
15. Akdemir A, Orsel S, Dag I. Validity, reliability and clinical use of Hamilton Depression Rating Scale. *Psikiyatri Psikoloji Psikofarmakoloji Dergisi* 1996; 4:251-9.
16. Koltuksuz U, Irmak MK, Karaman A, et al. Testicular nitric oxide levels after unilateral testicular torsion/detorsion in rats pretreated with caffeic acid phenethyl ester. *Urol Res* 2000; 28:360-3. [Abstract]
17. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. *Clin Chem* 1988; 34:497-500. [Abstract] / [PDF]
18. Durak I, Yurtarslan Z, Canbolat O, et al. A methodological approach to superoxide dismutase (SOD) activity assay based on inhibition of nitroblue tetrazolium (NBT) reduction. *Clin Chim Acta* 1993; 214:103-4. [Abstract]
19. Zupan G, Pilipovic K, Hrelja A, et al. Oxidative stress parameters in different rat brain structures after electroconvulsive shock-induced seizures. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; 32:771-7. [Abstract] / [Full Text] / [PDF]
20. Zupan G, Vitezić D, Mrišić J, et al. Effects of nimodipine, felodipine and amlodipine on electroconvulsive shock-induced amnesia in the rat. *Eur J Pharmacol* 1996; 310:103-6. [Abstract]
21. Yunoki M, Kawachi M, Ukita N, et al. Effects of lecithinized SOD and sequential change in SOD activity after cerebral contusion in rats. *Acta Neurochir* 1998; 71:142-5. [Abstract]
22. Selek S, Savas HA, Gergerlioglu HS, et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. *J Affect Disord* 2008; 107:89-94. [Abstract] / [Full Text] / [PDF]
23. Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. *J Affect Disord* 2001; 64:43-51. [Abstract] / [Full Text] / [PDF]
24. Ersoy MA, Selek S, Celik H, et al. Role of oxidative and antioxidative parameters in etiopathogenesis and prognosis of panic disorder. *Int J Neurosci* 2008; 118:1025-37. [Abstract] / [PDF]
25. Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. *Arch Med Res* 2007; 38:247-52. [Abstract] / [Full Text] / [PDF]
26. Kaushik G, Kaushik T, Khanduja S, et al. Cigarette smoke condensate promotes cell proliferation through disturbance in cellular redox homeostasis of transformed lung epithelial type-II cells. *Cancer Lett* 2008; 270:120-31. [Abstract] / [Full Text] / [PDF]
27. Allaouchiche B, Debon R, Goudable J, et al. Oxidative stress status during exposure to propofol, sevoflurane and desflurane. *Anesth Analg* 2001; 93:981-5. [Abstract] / [Full Text] / [PDF]
28. Ozturk E, Demirbilek S, But A, et al. Antioxidant properties of propofol and erythropoietin after closed head injury in rats. *Prog Neuropsychopharmacol Biol Psychiatry* 2005; 29:922-7. [Abstract] / [Full Text] / [PDF]